Excellus BlueCross BlueShield has joined a group of six Blue Cross Blue Shield affiliates who have refused to cover Aduhelm, Biogen’s Alzheimer’s medicine until it has been shown successful. Excellus is still classifying the medicine as “investigational” until more evidence of its efficacy becomes available. “Our health plan wants our members to have access to therapies that are safe, effective, and evidence-based as demonstrated by peer-reviewed clinical trials” said Excellus Vice President Elizabeth Martin.